Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

被引：223

作者：

Stone, R. M. ^{[1
]}

Fischer, T. ^{[2
]}

Paquette, R. ^{[3
]}

Schiller, G. ^{[3
]}

Schiffer, C. A. ^{[4
]}

Ehninger, G. ^{[5
]}

Cortes, J. ^{[6
]}

Kantarjian, H. M. ^{[6
]}

DeAngelo, D. J. ^{[1
]}

Huntsman-Labed, A. ^{[7
]}

Dutreix, C. ^{[7
]}

del Corral, A. ^{[8
]}

Giles, F. ^{[9
,10
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02215 USA

[2] Otto von Guericke Univ, Med Ctr, Dept Hematol Oncol, Magdeburg, Germany

[3] UCLA Med Ctr, Los Angeles, CA USA

[4] Karmanos Canc Inst, Detroit, MI USA

[5] Tech Univ Dresden, D-01062 Dresden, Germany

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Novartis Pharma AG, Basel, Switzerland

[8] Novartis Oncol, E Hanover, NJ USA

[9] Natl Univ Ireland, HRB Clin Res Facil, Galway, Ireland

[10] Trinity Coll Dublin, Dublin, Ireland

来源：

LEUKEMIA | 2012年 / 26卷 / 09期

关键词：

FMS-like tyrosine kinase 3 receptor; acute myeloid leukemia; midostaurin; PKC412; newly diagnosed; ACUTE MYELOGENOUS LEUKEMIA; RISK MYELODYSPLASTIC SYNDROME; INTERNAL TANDEM DUPLICATIONS; POOR-PROGNOSIS; MUTANT FLT3; WILD-TYPE; GROUP-B; MUTATIONS; PKC412; CYTOGENETICS;

D O I：

10.1038/leu.2012.115

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This phase 1b trial investigated several doses and schedules of midostaurin in combination with daunorubicin and cytarabine induction and high-dose cytarabine post-remission therapy in newly diagnosed patients with acute myeloid leukemia (AML). The discontinuation rate on the 50-mg twice-daily dose schedule was lower than 100 mg twice daily, and no grade 3/4 nausea or vomiting was seen. The complete remission rate for the midostaurin 50-mg twice-daily dose schedule was 80% (FMS-like tyrosine kinase 3 receptor (FLT3)-wild-type: 20 of 27 (74%), FLT3-mutant: 12 of 13 (92%)). Overall survival (OS) probabilities of patients with FLT3-mutant AML at 1 and 2 years (0.85 and 0.62, respectively) were similar to the FLT3-wild-type population (0.78 and 0.52, respectively). Midostaurin in combination with standard chemotherapy demonstrated high complete response and OS rates in newly diagnosed younger adults with AML, and was generally well tolerated at 50mg twice daily for 14 days. A phase III prospective trial is ongoing (CALGB 10603, NCT00651261).

引用

页码：2061 / 2068

页数：8

共 21 条

[1] A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML
Breitenbuecher, Frank
Markova, Boyka
Kasper, Stefan
Carius, Birgit
Stauder, Torsten
Boehmer, Frank D.
Masson, Kristina
Ronnstrand, Lars
Huber, Christoph
Kindler, Thomas
Fischer, Thomas
[J]. BLOOD, 2009, 113 (17) : 4063 - 4073
[2] Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461)
Byrd, JC
Mrózek, K
Dodge, RK
Carroll, AJ
Edwards, CG
Arthur, DC
Pettenati, MJ
Patil, SR
Rao, KW
Watson, MS
Koduru, PRK
Moore, JO
Stone, RM
Mayer, RJ
Feldman, EJ
Davey, FR
Schiffer, CA
Larson, RA
Bloomfield, CD
[J]. BLOOD, 2002, 100 (13) : 4325 - 4336
[3] Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
DeAngelo, Daniel J.
Stone, Richard M.
Heaney, Mark L.
Nimer, Stephen D.
Paquette, Ronald L.
Klisovic, Rebecca B.
Caligiuri, Michael A.
Cooper, Michael R.
Lecerf, Jean-Michel
Karol, Michael D.
Sheng, Shihong
Holford, Nick
T Curtin, Peter
Druker, Brian J.
Heinrich, Michael C.
[J]. BLOOD, 2006, 108 (12) : 3674 - 3681
[4] Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Fischer, Thomas
Stone, Richard M.
DeAngelo, Daniel J.
Galinsky, Ilene
Estey, Elihu
Lanza, Carlo
Fox, Edward
Ehninger, Gerhard
Feldman, Eric J.
Schiller, Gary J.
Klimek, Virginia M.
Nimer, Stephen D.
Gilliland, D. Gary
Dutreix, Catherine
Huntsman-Labed, Alice
Virkus, Jodi
Giles, Francis J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (28) : 4339 - 4345
[5] Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
Kayser, Sabine
Schlenk, Richard F.
Londono, Martina Correa
Breitenbuecher, Frank
Wittke, Kerstin
Du, Juan
Groner, Silja
Spaeth, Daniela
Krauter, Juergen
Ganser, Arnold
Doehner, Hartmut
Fischer, Thomas
Doehner, Konstanze
[J]. BLOOD, 2009, 114 (12) : 2386 - 2392
[6] The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
Kottaridis, PD
Gale, RE
Frew, ME
Harrison, G
Langabeer, SE
Belton, AA
Walker, H
Wheatley, K
Bowen, DT
Burnett, AK
Goldstone, AH
Linch, DC
[J]. BLOOD, 2001, 98 (06) : 1752 - 1759
[7] In vitro studies of a FM inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
Levis, M
Pham, R
Smith, BD
Small, D
[J]. BLOOD, 2004, 104 (04) : 1145 - 1150
[8] Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
Levis, Mark
Brown, Patrick
Smith, B. Douglas
Stine, Adam
Pham, Rosalyn
Stone, Richard
DeAngelo, Daniel
Galinsky, Ilene
Giles, Frank
Estey, Elihu
Kantarjian, Hagop
Cohen, Pamela
Wang, Yanfeng
Roesel, Johannes
Karp, Judith E.
Small, Donald
[J]. BLOOD, 2006, 108 (10) : 3477 - 3483
[9] The first human acute myeloid leukemia genome ever fully sequenced
Falini, Brunangelo
[J]. HAEMATOLOGICA, 2024, 109 (01) : 1 - 2
[10] Manley PW, 2003, 94 ANN M AM ASS CANC

← 1 2 3 →